News IXICO plc

Equities

IXI

GB00BFXR4C20

Biotechnology & Medical Research

Market Closed - London S.E. Other stock markets 11:35:06 2026-05-11 EDT			5-day change	1st Jan Change
6.625 ^GBX	0.00%		-3.64%	-43.62%

04-21	EARNINGS AND TRADING: Mpac swings to loss; Gear4music sales rise 30%	AN
04-21	Ixico plc Provides Earnings Guidance for the First Half Ended 31 March 2026	CI

All News

Mentions Relevance

04-21	Ixico plc Provides Earnings Guidance for the First Half Ended 31 March 2026	CI
04-07	Ixico Completes Retail Stock Offering	MT
03-31	EARNINGS AND TRADING: Future takes "cautious view"; Ixico's fundraise	AN
03-31	Ixico Raises GBP10 Million via Share Placements, Subscription	MT
03-26	Ixico plc and Medidata Collaborate to Create Advanced Neuroimaging Clinical Trials Platform	CI
02-26	IXICO plc Presents Automated Capabilities to Measure Brain Volume Loss on Magnetic Resonance Imaging Within its IXI Platform	CI
02-12	IXICO plc Announces c.£1.5 Million Contract Extension on Global Phase 2 Clinical Trial	CI
02-12	Ixico announces about 1.5 mln stg contract extension	RE
02-05	Ixico Names Chief Commercial Officer	MT
02-05	IXICO plc Appoints Tanya Voloshen as Chief Commercial Officer	CI
12-26	IXICO plc - Analyst/Investor Day
12-17	IXICO : AGM Notice 2026	PU
12-10	IXICO plc, 2025 Earnings Call, Dec 09, 2025
12-09	IXICO : ANNUAL RESULTS PRESENTATION (2025 Final Results Presentation FINAL v2)	PU
12-09	IXICO plc Reports Earnings Results for the Full Year Ended September 30, 2025	CI
12-09	Earnings Flash (IXI.L) Ixico plc Reports FY25 Revenue GBP6.5M	MT
12-04	AI-Driven Recruitment for Alzheimer’s Disease Clinical Trials: A Pilot Analysis on the A4 Study Dataset	PU
12-01	IXICO plc Announces Scientific Advisory Board Appointments, Effective December 1, 2025	CI
12-01	IXICO : strengthens Scientific Advisory Board with two prominent global Alzheimer’s Disease and vascular experts	PU
11-17	Ixico wins GBP3.7 million deal to support Huntington's Disease trial	AN
11-17	AIM WINNERS & LOSERS: OptiBiotix and Ixico rise on deal wins	AN
11-17	Ixico announces phase 3 clinical trial contract win worth over 3.5 mln stg over four years	RE
11-17	IXICO : Global Phase 3 Clinical Trial Contract Win	PU
11-17	IXICO plc Announces Global Phase 3 Clinical Trial Contract Win Worth over £3.5 Million	CI
11-03	IXICO : CAPITAL MARKETS DAY PRESENTATION (Capital Markets Day 30 October 2025 FINAL 1)	PU